$2.60
+0.12 (+4.84%)
Open$2.50
Previous Close$2.48
Day High$2.64
Day Low$2.50
52W High$6.52
52W Low$2.20
Volume—
Avg Volume48.8K
Market Cap20.14M
P/E Ratio—
EPS$-7.41
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,487.7% upside
Current
$2.60
$2.60
Target
$41.28
$41.28
$32.58
$41.28 avg
$58.47
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.64M | 1.62M | 1.37M |
| Net Income | -247,177 | -249,222 | -229,259 |
| Profit Margin | -15.1% | -15.4% | -16.8% |
| EBITDA | -331,691 | -310,875 | -283,649 |
| Free Cash Flow | -127,219 | -197,557 | -123,470 |
| Rev Growth | +20.7% | +12.0% | +3.1% |
| Debt/Equity | 0.09 | 0.11 | 0.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |